ストックスクリーナーアプリを入手
1.22
3.94%
-0.05
プレマーケット:
1.27
0.05
+4.10%
前日終値:
$1.27
開ける：
$1.27
24時間の取引高:
84,502
Relative Volume:
0.05
時価総額：
$87.29M
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
+15.09%
1か月 パフォーマンス:
+24.73%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$1.16
$1.27
1週間の範囲:
$1.09
$1.3899
52週間の値動き範囲:
$0.85
$2.87
Citius Oncology Inc Stock (CTOR) Company Profile
CTOR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
1.22 | 87.29M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
167.53 | 75.58B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.82 | 24.72B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
145.88 | 14.77B | 2.24B | 385.90M | 440.10M | 3.73 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-27 | 開始されました | Maxim Group | Buy |
Citius Oncology Inc (CTOR) 最新ニュース
Citius Oncology, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - 69News WFMZ-TV
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules - BioSpace
Citius Pharmaceuticals Secures $3M Through Strategic Share Offering with 5-Year Warrants - StockTitan
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025 - PR Newswire
Citius Oncology to explore strategic alternatives - Yahoo Finance
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives - The Malaysian Reserve
Citius Pharma Reports 2024 Financial Results and Business Update - MSN
Citius Pharmaceuticals upgraded to Buy from Hold at D. Boral Capital - Yahoo Finance
Citius Pharmaceuticals (NASDAQ: CTXR) Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - Defense World
Citius Oncology, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update - The Malaysian Reserve
Citius Pharmaceuticals Inc. (CTXR) reports earnings - Quartz
Citius Pharmaceuticals stock hits 52-week low at $2.52 - Investing.com
Major Improvements In Citius Oncology Inc (CTOR) Stock Need To Be Considered - Stocks Register
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce LYMPHIR™ (Denileukin Diftitox-cxdl) Added to National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - The Eastern Progress Online
“Market Movers: CTOR, CTNT, PNPN.V, KITT, SHIM – More Stocks Inside To Watch” - Barchart
Why Credo Technology Group Shares Are Trading Higher By 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Maxim Group Begins Coverage on Citius Oncology (NASDAQ:CTOR) - Defense World
Loss-Making Citius Oncology, Inc. (NASDAQ:CTOR) Expected To Breakeven In The Medium-Term - Simply Wall St
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - Yahoo Finance
Citius Pharmaceuticals to Host Investor Call to Discuss Topline Results of Phase 3 Trial of Mino-Lok Antibiotic Lock Solution - Marketscreener.com
Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff - Marketscreener.com
Citius Pharma Advances Mino-Lok After Successful FDA Meeting, Phase 3 Trial Results | CTXR Stock News - StockTitan
Citius Pharma shares hit new low after reverse stock split - Kursiv Media
CTOR stock touches 52-week low at $0.9 amid market challenges - Investing.com Canada
CTOR stock touches 52-week low at $0.9 amid market challenges By Investing.com - Investing.com South Africa
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split to Maintain Nasdaq Listing | CTXR Stock News - StockTitan
Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split - Yahoo Finance
Citius Pharmaceuticals reports positive early stage results of cancer combo treatment - MSN
Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - BioSpace
Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - BioSpace
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan
Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan
Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com
Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - BioSpace
Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma
CTOR stock touches 52-week low at $1.02 amid market challenges - Investing.com India
CTOR stock touches 52-week low at $1.02 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges By Investing.com - Investing.com South Africa
CTOR stock touches 52-week low at $1.29 amid market challenges - Investing.com
Citius Pharmaceuticals stock hits 52-week low at $0.48 - Investing.com
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2024 - Marketscreener.com
Citius Oncology (NASDAQ:CTOR) Stock Quotes, Forecast and News Summary - Benzinga
Citius Oncology Inc (CTOR) 財務データ
Citius Oncology Inc (CTOR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
2.14%
大文字化:
|
ボリューム (24 時間):